Bexarotene treatment in C6 glioma cells impedes NF-κB activation by amplifying PPARγ expression, leading to the regulation of apoptosis, DNA damage, and ROS production, among other processes, consequently exerting anti-proliferative and cytotoxic effects [54]. The gene discussed is NFKB1; the disease is glioma.